Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis-Reference-Cited by-同舟云学术

Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis

Published:2020-08 Issue:2 Volume:99 Page:82-89
ISSN:0923-1811
Container-title:Journal of Dermatological Science
language:en
Short-container-title:Journal of Dermatological Science

Author:

Nakagawa Hidemi,Iizuka Hajime,Nemoto Osamu,Shimabe Munetake,Furukawa Yasunobu,Kikuta Natsuko,Ootaki Kenji

Funder

Kyowa Kirin Co., Ltd

Publisher

Elsevier BV

Subject

Dermatology,Molecular Biology,Biochemistry

Reference39 articles.

1. Epidemiology of atopic dermatitis: a review;DaVeiga;Allergy Asthma Proc.,2012

2. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health;Shaw;J. Invest. Dermatol.,2011

3. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation;Schmitt;J. Allergy Clin. Immunol.,2013

4. New pathogenic and therapeutic paradigms in atopic dermatitis;Malajian;Cytokine,2015

5. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches;Leung;J. Allergy Clin. Immunol.,2014

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments;International Immunopharmacology;2024-09

2. Current and Emerging Biologics for Atopic Dermatitis;Immunology and Allergy Clinics of North America;2024-09

3. Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations;Journal of Allergy and Clinical Immunology;2024-07

4. Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy;Current Pharmaceutical Biotechnology;2024-06-25

5. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02